COMMUNIQUÉS West-GlobeNewswire

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
27/03/2026
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond [...]
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
27/03/2026
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase [...]
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
27/03/2026
Company continues to evaluate strategic options to maximize shareholder value WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative [...]
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
27/03/2026
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle [...]
Precision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock
27/03/2026
GARDNER, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
27/03/2026
Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ( “ Clearmind ” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
27/03/2026
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]
Arletta Pharma Solutions Announces Positive Results from Phase II Clitoral Doppler Duplex Ultrasound Study of Lybrido™ Combination Targeting Female Sexual Dysfunction
27/03/2026
www.arlettapharmasolutions.com More than 60% average improvement in clitoral blood flow observed with both dose-combinations Statistical significance achieved with new high dose-combination despite small sample size [...]
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
27/03/2026
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
27/03/2026
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical proof-of-concept [...]
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
27/03/2026
MILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge 1 , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security- [...]
Johnson & Johnson’s DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
27/03/2026
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma 1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to [...]
Articles of Association for Novo Nordisk A/S 2026
27/03/2026
Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026
Notification of managers’ transactions
27/03/2026
ANNOUNCEMENT NO. 306 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Notification of managers’ transactions
27/03/2026
ANNOUNCEMENT NO. 305 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Zelluna ASA – Mandatory notification of trade
27/03/2026
Oslo, Norway, 27 March 2026 - Anders Tuv, Managing Director in Radforsk Invest, and Chairperson and co-founder of Zelluna ASA ( Zelluna ), has today entered into an agreement with Radforsk Investeringsstiftelse ( [...]
UCB - Convening Notice to the General Meeting of the Shareholders 2026
27/03/2026
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “ General Meeting ”) which will be held on Thursday, 30 April 2026 [...]
IBA réalise des résultats solides pour l'exercice 2025, avec une exécution maîtrisée dans tous les segments
27/03/2026
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats annuels 2025 Louvain-La-Neuve, Belgique, 27 mars 2026 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour l' [...]
Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years
27/03/2026
Submission based on topline data from clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27 [...]

Pages